Development, Optimization and Characterization of Oral Solid Self-Nanoemulsifying Drug Delivery Systems (S-SNEDDS) of Repaglinide Tablets for Type – II Diabetes

Author(s)

Sharma, R., Katageri, S.B.

Author's Affiliation

Abstract

The present studies entail formulation development of novel solid self-nanoemulsifying drug delivery systems (S-SNEDDS) of repaglinide for successful oral delivery, and evaluation of their in vitro. Preliminary solubility studies were carried out and pseudoternary phase diagrams were constructed using blends of oil (Caprypol 90), surfactant (Labrasol), and cosurfactant (Transcutol P). The SNEDDS were systematically optimized by response surface methodology employing 3³-Box–Behnken design. The prepared SNEDDS were characterized for viscosity, refractive index, globule size, zeta potential, and TEM. Optimized liquid SNEDDS were formulated into free flowing granules by adsorption on the porous carriers like Aerosil 200, Sipernat 22S, Sylysia 350, Zeopharm 600, Neusilin US2, Neusilin UFL2 and compressed into tablets. In vitro dissolution studies of S-SNEDDS revealed 2.5 – 5-fold increased in dissolution rate of the drug due to enhanced solubility. Solid-state characterization of S-SNEDDS using FTIR, DSC and powder XRD studies confirmed lack of any significant interaction of drug with lipidic excipients and porous carriers. Further, the accelerated stability studies for 6 months revealed that S-SNEDDS are found to be stable without any change in physiochemical properties. Thus, the present studies demonstrated the solubility and may be bioavability enhancement potential of porous carriers based S-SNEDDS for a BCS class II anti diabetic drug, repaglinide.

Keywords

Repaglinide, BCS Class II, Self Nanoemulifying Drug Delivery Systems, Porous Carrier, Solid State Characterization

Cite This Article

Sharma, R., Katageri, S.B. (2015). Development, Optimization and Characterization of Oral Solid Self-Nanoemulsifying Drug Delivery Systems (S-SNEDDS) of Repaglinide Tablets for Type – II Diabetes, International Journal for Pharmaceutical Research Scholars (IJPRS), 4(3), 123-138.